Retevmo® (selpercatinib) A precision-based therapy for certain RET-driven cancers-Focus on Advanced or Metastatic Thyroid Cancer

Presented by Dr. Todd Frieze

Join us to review the clinical data for LIBRETTO-001, examine the efficacy and safety profiles, and explore the dosing, dose modifications, administration, and appropriate testing methods for a biomarker-driven therapy. This program aims to help you identify patients who may be eligible for this treatment option.

LENVIMA®: A First-Line Treatment for Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Virtual Program, presented on behalf of Eisai Inc.

This satellite symposium will educate HCPs on LENVIMA as a 1L option for treatment of locally recurrent or metastatic, progressive, RAI-R DTC including an overview of the SELECT trial and efficacy data as well as safety profile and strategies to recognize, monitor, and manage adverse reactions (ARs) that may occur with LENVIMA. Attendees will also have the opportunity to review patient case studies and engage in discussion regarding the treatment selection process.
This program is sponsored by Eisai Inc. For more information on LENVIMA, please visit www.lenvima.com/hcp and https://www.lenvima.com/-/media/Project/EISAI/Lenvima/PDF/prescribing-information.pdf